Status update in the use of cell-penetrating peptides for the delivery of macromolecular therapeutics

References

• Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988 Dec;55(6):1189–1193.
   PubMed Web of Science ®Google Scholar
• Langel Ü. CPP, cell-penetrating peptides. 1 ed. Singapore: Springer; 2019.
   Google Scholar
• Kardani K, Milani A,H, Shabani S, et al. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin Drug Deliv. 2019 Nov;16(11):1227–1258.
   PubMed Web of Science ®Google Scholar
• Peraro L, Kritzer JA. Emerging methods and design principles for cell-penetrant peptides. Angew Chem Int Ed Engl. 2018 Sep;57(37):11868–11881.
   PubMed Web of Science ®Google Scholar
• Uusna J, Langel K, Langel Ü. Toxicity, immunogenicity, uptake, and kinetics methods for CPPs. Methods Mol Biol. 2015;1324:133–148.
   PubMedGoogle Scholar
• Pei D, Buyanova M. Overcoming endosomal entrapment in drug delivery. Bioconjug Chem. 2019 Feb;30(2):273–283.
   PubMed Web of Science ®Google Scholar
• Kurrikoff K, Gestin M, Langel Ü. Recent in vivo advances in cell-penetrating peptide-assisted drug delivery. Expert Opin Drug Deliv. 2016 Mar;13(3):373–387.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Saleh MN, Infante JR, et al. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J clin oncol. 2017;35(15_suppl):2505.
   Google Scholar
• Bennett G, Lutz R, Park P, et al. Abstract 1167: development of BT1718, a novel bicycle drug conjugate for the treatment of lung cancer. Cancer Res. 2017;77(13 Supplement):1167.
   Google Scholar
• Lulla RR, Goldman S, Yamada T, et al. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2016 Sep;18(9):1319–1325.
   PubMed Web of Science ®Google Scholar
• Feni L, Parente S, Robert C, et al. Kiss and run: promoting effective and targeted cellular uptake of a drug delivery vehicle composed of an integrin-targeting diketopiperazine peptidomimetic and a cell-penetrating peptide. Bioconjug Chem. 2019 Jul;30(7):2011–2022.
   PubMed Web of Science ®Google Scholar
• Säälik P, Lingasamy P, Toome K, et al. Peptide-guided nanoparticles for glioblastoma targeting. J Control Release. 2019 Aug;308:109–118.
   PubMed Web of Science ®Google Scholar
• Gaston J, Maestrali N, Lalle G, et al. Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions. Sci Rep. 2019 Dec;9(1):18688.
   PubMedGoogle Scholar
• Kumthekar P, Tang SC, Brenner AJ, et al. ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases. Clin Cancer Res. 2020 Jan;26:2789–2799.
   PubMed Web of Science ®Google Scholar
• Han H, Hou Y, Chen X, et al. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J Am Chem Soc. 2020 Mar;142(10):4944–4954.
   PubMed Web of Science ®Google Scholar
• Juang V, Chang CH, Wang CS, et al. pH-responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy. Small. 2019 Dec;15(49):e1903296.
   PubMed Web of Science ®Google Scholar
• Ihsanullah KM, Kumar BN, Zhao Y, et al. Stepwise-activatable hypoxia triggered nanocarrier-based photodynamic therapy for effective synergistic bioreductive chemotherapy. Biomaterials. 2020 Jul;245:119982.
   PubMed Web of Science ®Google Scholar
• Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004 Dec;101(51):17867–17872.
   PubMed Web of Science ®Google Scholar
• Künnapuu K, Veiman K-L, Porosk L, et al. Tumor gene therapy by systemic delivery of plasmid DNA with cell penetrating peptides. FASEB BioAdv. 2018;1(2):105–114.
   PubMedGoogle Scholar
• Guo F, Fu Q, Zhou K, et al. Matrix metalloprotein-triggered, cell penetrating peptide-modified star-shaped nanoparticles for tumor targeting and cancer therapy. J Nanobiotechnology. 2020 Mar;18(1):48.
   PubMed Web of Science ®Google Scholar
• Hingorani DV, Crisp JL, Doan MK, et al. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials. 2020 Jul;248:120032.
   PubMed Web of Science ®Google Scholar
• Arrouss I, Nemati F, Roncal F, et al. Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS One. 2013;8(4):e60816.
   PubMed Web of Science ®Google Scholar
• Andrini L, Marin GH, Inda AM, et al. Anti-tumoral effect of a cell penetrating and interfering peptide targeting PP2A/SET interaction. Folia Med (Plovdiv). 2020 Mar;62(1):31–36.
   PubMedGoogle Scholar
• Sogaard CK, Blindheim A, Rost LM, et al. “Two hits - one stone”; increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signaling. Oncotarget. 2018 Aug 21;9(65):32448–32465.
   PubMedGoogle Scholar
• Søgaard CK, Nepal A, Petrovic V, et al. Targeting the non-canonical roles of PCNA modifies and increases the response to targeted anti-cancer therapy. Oncotarget. 2019 Dec;10(68):7185–7197.
   PubMedGoogle Scholar
• Nedal A, Ræder SB, Dalhus B, et al. Peptides containing the PCNA interacting motif APIM bind to the β-clamp and inhibit bacterial growth and mutagenesis. Nucleic Acids Res. 2020 Jun;48(10):5540–5554.
   PubMed Web of Science ®Google Scholar
• Jaraíz-Rodríguez M, Talaverón R, García-Vicente L, et al. Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo. Neuro Oncol. 2020 Apr;22(4):493–504.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bu H, Yu J, et al. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3. Theranostics. 2019;9(10):2882–2896.
   PubMed Web of Science ®Google Scholar
• Dai Y, Yue N, Gong J, et al. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α. Eur J Med Chem. 2020 Feb;187:111967.
   PubMed Web of Science ®Google Scholar
• Gait MJ, Arzumanov AA, McClorey G, et al. Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment. Nucleic Acid Ther. 2019 Feb;29(1):1–12.
   PubMed Web of Science ®Google Scholar
• Shabanpoor F, Hammond SM, Abendroth F, et al. Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy. Nucleic Acid Ther. 2017 Jun;27(3):130–143.
   PubMed Web of Science ®Google Scholar
• Klein AF, Varela MA, Arandel L, et al. Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice. J Clin Invest. 2019 Nov;129(11):4739–4744.
   PubMed Web of Science ®Google Scholar
• Henning-Knechtel A, Kumar S, Wallin C, et al. Designed cell-penetrating peptide inhibitors of amyloid-beta aggregation and cytotoxicity. Cell Rep Phys Sci. 2020 Feb 26;1(2):100014.
   Google Scholar
• Qu J, Ren X, Xue F, et al. Specific knockdown of α-synuclein by peptide-directed proteasome degradation rescued its associated neurotoxicity. Cell Chem Biol. 2020 Apr;27:763.
   Web of Science ®Google Scholar
• Arora S, Sharma D, Singh J. GLUT-1: an effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier. ACS Chem Neurosci. 2020 May;11:1620–1633.
   Web of Science ®Google Scholar
• Rodrigues BDS, Kanekiyo T, Singh J. Nerve growth factor gene delivery across the blood-brain barrier to reduce beta amyloid accumulation in AD mice. Mol Pharm. 2020 Apr;17:2054–2063.
   PubMedGoogle Scholar
• Dos Santos Rodrigues B, Arora S, Kanekiyo T, et al. Efficient neuronal targeting and transfection using RVG and transferrin-conjugated liposomes. Brain Res. 2020 May;1734:146738.
   PubMed Web of Science ®Google Scholar
• Khafagy ES, Kamei N, Fujiwara Y, et al. Systemic and brain delivery of leptin via intranasal coadministration with cell-penetrating peptides and its therapeutic potential for obesity. J Control Release. 2020 Mar;319:397–406.
   PubMed Web of Science ®Google Scholar
• Samaridou E, Walgrave H, Salta E, et al. Nose-to-brain delivery of enveloped RNA - cell permeating peptide nanocomplexes for the treatment of neurodegenerative diseases. Biomaterials. 2020 Feb;230:119657.
   PubMed Web of Science ®Google Scholar
• Kurrikoff K, Langel Ü. Recent CPP-based applications in medicine. Expert Opin Drug Deliv. 2019 Nov;16(11):1183–1191.
   PubMed Web of Science ®Google Scholar
• Ishiguro S, Alhakamy NA, Uppalapati D, et al. Combined local pulmonary and systemic delivery of AT2R gene by modified TAT peptide nanoparticles attenuates both murine and human lung carcinoma xenografts in mice. J Pharm Sci. 2017 Jan;106(1):385–394.
   PubMed Web of Science ®Google Scholar
• Qiu M, Ouyang J, Wei Y, et al. Selective cell penetrating peptide-functionalized envelope-type chimeric lipopepsomes boost systemic RNAi therapy for lung tumors. Adv Healthc Mater. 2019 Jun;24:e1900500.
   Google Scholar
• Kim Y, Hwang S, Khalmuratova R, et al. α-Helical cell-penetrating peptide-mediated nasal delivery of resveratrol for inhibition of epithelial-to-mesenchymal transition. J Control Release. 2020 Jan;317:181–194.
   PubMed Web of Science ®Google Scholar
• Veiman K-L, Künnapuu K, Lehto T, et al. PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo. J Control Release. 2015 Jul 10;209:238–247.
   PubMed Web of Science ®Google Scholar
• Osman G, Rodriguez J, Chan SY, et al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J Control Release. 2018 Sep;285:35–45.
   PubMed Web of Science ®Google Scholar
• Kurrikoff K, Freimann K, Veiman KL, et al. Effective lung-targeted RNAi in mice with peptide-based delivery of nucleic acid. Sci Rep. 2019 Dec 27;9(1):19926.
   PubMedGoogle Scholar
• Kurrikoff K, Veiman KL, Künnapuu K, et al. Effective in vivo gene delivery with reduced toxicity, achieved by charge and fatty acid -modified cell penetrating peptide. Sci Rep. 2017 Dec;7(1):17056.
   PubMedGoogle Scholar
• Johnson LN, Cashman SM, Read SP, et al. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. Vision Res. 2010 Mar;50(7):686–697.
   PubMed Web of Science ®Google Scholar
• Andaloussi SEL, Lehto T, Mäger I, et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 2011 MAY;39(9):3972–3987.
   PubMed Web of Science ®Google Scholar
• Schiroli D, Gómara MJ, Maurizi E, et al. Effective in vivo topical delivery of siRNA and gene silencing in intact corneal epithelium using a modified cell-penetrating peptide. Mol Ther Nucleic Acids. 2019 Sep;17:891–906.
   PubMedGoogle Scholar
• Zhang P, Moreno R, Lambert PF, et al. Cell-penetrating peptide inhibits retromer-mediated human papillomavirus trafficking during virus entry. Proc Natl Acad Sci U S A. 2020 Mar;117(11):6121–6128.
   PubMed Web of Science ®Google Scholar
• Deprey K, Becker L, Kritzer J, et al. Trapped! A critical evaluation of methods for measuring total cellular uptake versus cytosolic localization. Bioconjug Chem. 2019 Apr;30(4):1006–1027.
   PubMed Web of Science ®Google Scholar
• Lehto T, Kurrikoff K, Langel Ü. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv. 2012 Jul;9(7):823–836.
   PubMed Web of Science ®Google Scholar